Zacks: Analysts Anticipate Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Will Post Earnings of $0.99 Per Share

Equities research analysts forecast that Collegium Pharmaceutical, Inc. (NASDAQ:COLLGet Rating) will post $0.99 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Collegium Pharmaceutical’s earnings. The highest EPS estimate is $1.03 and the lowest is $0.87. Collegium Pharmaceutical reported earnings of $0.41 per share in the same quarter last year, which would indicate a positive year over year growth rate of 141.5%. The business is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Collegium Pharmaceutical will report full-year earnings of $5.59 per share for the current year, with EPS estimates ranging from $4.75 to $6.21. For the next year, analysts expect that the company will post earnings of $7.44 per share, with EPS estimates ranging from $6.56 to $8.97. Zacks’ EPS averages are an average based on a survey of research firms that cover Collegium Pharmaceutical.

A number of equities research analysts have commented on COLL shares. TheStreet raised shares of Collegium Pharmaceutical from a “c+” rating to a “b-” rating in a report on Thursday, March 3rd. Piper Sandler lifted their price objective on Collegium Pharmaceutical from $36.00 to $42.00 and gave the company an “overweight” rating in a report on Tuesday, February 22nd. StockNews.com lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, April 2nd. Zacks Investment Research upgraded Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating and set a $22.00 price objective on the stock in a research note on Thursday, March 3rd. Finally, HC Wainwright upped their price objective on Collegium Pharmaceutical from $26.00 to $29.00 and gave the stock a “buy” rating in a report on Tuesday, February 15th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Collegium Pharmaceutical currently has a consensus rating of “Buy” and a consensus price target of $31.00.

Shares of NASDAQ:COLL opened at $19.26 on Friday. The firm has a market capitalization of $653.36 million, a P/E ratio of 11.40, a price-to-earnings-growth ratio of 0.21 and a beta of 0.96. Collegium Pharmaceutical has a 12-month low of $17.07 and a 12-month high of $25.66. The company has a quick ratio of 1.07, a current ratio of 1.13 and a debt-to-equity ratio of 0.99. The firm has a fifty day moving average of $19.39 and a two-hundred day moving average of $19.25.

In other news, EVP Scott Dreyer sold 10,559 shares of the company’s stock in a transaction dated Friday, February 18th. The stock was sold at an average price of $21.61, for a total value of $228,179.99. The sale was disclosed in a filing with the SEC, which is accessible through this link. 5.18% of the stock is owned by company insiders.

Large investors have recently made changes to their positions in the business. Royal Bank of Canada boosted its stake in shares of Collegium Pharmaceutical by 344.3% in the 2nd quarter. Royal Bank of Canada now owns 3,110 shares of the specialty pharmaceutical company’s stock worth $74,000 after buying an additional 2,410 shares during the last quarter. Virginia Retirement Systems ET AL lifted its position in Collegium Pharmaceutical by 24.6% during the 3rd quarter. Virginia Retirement Systems ET AL now owns 42,100 shares of the specialty pharmaceutical company’s stock valued at $831,000 after acquiring an additional 8,300 shares during the period. New York State Teachers Retirement System raised its position in shares of Collegium Pharmaceutical by 4.9% in the 3rd quarter. New York State Teachers Retirement System now owns 13,797 shares of the specialty pharmaceutical company’s stock worth $272,000 after purchasing an additional 640 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new stake in Collegium Pharmaceutical in the 3rd quarter worth about $28,000. Finally, Fisher Asset Management LLC grew its stake in shares of Collegium Pharmaceutical by 34.8% during the 3rd quarter. Fisher Asset Management LLC now owns 20,349 shares of the specialty pharmaceutical company’s stock valued at $402,000 after purchasing an additional 5,254 shares during the period.

About Collegium Pharmaceutical (Get Rating)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.

Featured Stories

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.